A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter studyFederica Miglietta, M.V. Dieci, B. Fernandes et al.|European Journal of Cancer|2022Cited by 0